

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/717,868		11/19/2003	Ingo Konetzki	1/1428	9343	
28501	7590	06/13/2005		EXAM	EXAMINER	
MICHAEL			SEAMAN, D MARGARET M			
BOEHRINGER INGELHEIM CORPORATION 900 RIDGEBURY ROAD				ART UNIT	PAPER NUMBER	
P. O. BOX 368				1625		
RIDGEFIELD, CT 06877-0368				DATE MAILED: 06/13/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
,	10/717,868	KONETZKI ET AL.					
Office Action Summary	Examiner	Art Unit					
	D. Margaret Seaman	1625					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1) Responsive to communication(s) filed on	_•						
	action is non-final.						
3) Since this application is in condition for allowar							
closed in accordance with the practice under E	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4)⊠ Claim(s) <u>1-15</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>1-15</u> is/are rejected.	6)⊠ Claim(s) <u>1-15</u> is/are rejected.						
	,,						
8) Claim(s) are subject to restriction and/or	r election requirement.						
Application Papers							
9) The specification is objected to by the Examine	г.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
<u>.</u>							
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)⊠ All b)□ Some * c)□ None of:							
1.⊠ Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s) 4) Martine of Defendance Cited (DTO 202)							
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date							
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)		atent Application (PTO-152)					
Paper No(s)/Mail Date 6)							

DETAILED ACTION

This application was filed 11/19/2003 and claims benefit of Provisional Application 60/446,668 (2/11/2003) which claims benefit of Germany $102\,56\,080$ (11/29/2002). Claims 1-15 are before the Examiner.

Claim Rejections - 35 USC § 112

- The following is a quotation of the second paragraph of 35 U.S.C. 112:
 The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 2. Claims 1-15 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Specifically, claims 1-15 are ambiguous due to the claims being drawn to "tiotropium" (substance "1"). A search on Registry came up with eight different compounds having the name "tiotropium". Clarification is required.

Specifically, claims 5-6 and 9-13 are ambiguous due to the claims being drawn to the composition of a combination of active substances "1 and 2". However, claim 1 is drawn to the composition of substances "1 and 2". What is substance "2"? Clarification is required.

Application/Control Number: 10/717,868 Page 3

Art Unit: 1625

Claim Rejections - 35 USC § 103

- 3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 4. The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:
 - 1. Determining the scope and contents of the prior art.
 - 2. Ascertaining the differences between the prior art and the claims at issue.
 - 3. Resolving the level of ordinary skill in the pertinent art.
 - 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 5. Claims 1-15 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 00/75114 in view of WO 02/45703.

WO 00 teaches compounds of formula (I) that encompass the instant claimed formula 2' to treat obstructive or inflammatory airway diseases in combination with other active ingredients such as tiotropium bromide (see page 17) for use as an inhalant or solid drug.

WO00 does not specifically teach the instant compound of formula 2' but teaches formula (I) with a small Markush using formula (III) that would make the instant compound obvious.

WO 00 does not specifically teach weight ratios, inhalable powder or propellants.

WO 02 teaches a combination of two active ingredients to treat obstructive or inflammatory airway diseases. The first compound is the compound of the instant formula 2′. The second is a corticosteroid, which is not the instantly claimed formula 1. However, WO 02 teaches propellants, inhalable forms, dispersions, nebulizers, particle size and weight ratios.

It would have been obvious to one of ordinary skill in the art to use the compound of the instantly claimed formula 2' as taught by WO 02 with a tiotropium (instantly claimed formula 1) as taught by WO 00 to treat obstructive or inflammatory airway diseases. Rationale: WO 00 teaches a Markush plus tiotropium to treat obstructive or inflammatory airway diseases and WO 02 teaches the instant claimed 2' in combination with another active ingredient to treat obstructive or inflammatory airway diseases. The combination of the two references would have been within the skill of the ordinary artisan.

Art Unit: 1625

Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. Margaret Seaman whose telephone number is 571-272-0694. The examiner can normally be reached on 630am-4pm, First Friday Off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecelia Tsang can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Margaret Seaman Primary Examiner Art Unit 1625

dms